Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (13925)	1/30/1998 12:21:00 PM
From: Scusami	Read Replies (1) \| Respond to of 32384

Henry: You wrote: <LGND's diabetes compounds are oral. Inhaler news would have more of an effect on companies that rely on injected drugs (like LLY's insulin) and it would put more pressure on LLY to develop oral compounds like Targretin.> Ask yourself: How many retail people understand that point? You being closer to the industry understand that, but the laymen may not. Their perception may be that the competition is getting the edge on Ligand. < I suspect that technical factors and margin calls are providing the recent selling pressure.> This certainly could be a factor! The question is what caused this recent drop in interest (technical factors) and, hence, price. It must be connected with the lowering of investor expectations for one reason or another and the desire to put that money to work on a perceived "better deal or opportunity". Scusami